Item Type | Name |
Academic Article
|
The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer.
|
Academic Article
|
Clinicopathologic factors associated with involved margins after breast-conserving surgery for invasive lobular carcinoma.
|
Academic Article
|
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
|
Academic Article
|
Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy.
|
Concept
|
Neoadjuvant Therapy
|
Academic Article
|
Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma.
|
Academic Article
|
Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome.
|
Academic Article
|
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.
|
Academic Article
|
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
|
Academic Article
|
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.
|
Academic Article
|
The role of neoadjuvant therapy in surgically resectable esophageal cancer.
|
Academic Article
|
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
|
Academic Article
|
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.
|
Academic Article
|
Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation.
|
Academic Article
|
Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas.
|
Academic Article
|
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.
|
Academic Article
|
Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas.
|
Academic Article
|
Now and later? The sticky question of lymph node management in patients receiving preoperative chemotherapy.
|
Academic Article
|
Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer.
|
Academic Article
|
Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
|
Academic Article
|
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
|
Academic Article
|
Expanding the indications for sentinel lymph node surgery in breast cancer.
|
Academic Article
|
Lymphadenectomy for isolated lymph node metastasis from extremity soft-tissue sarcomas.
|
Academic Article
|
Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy.
|
Academic Article
|
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
|
Academic Article
|
USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer.
|
Academic Article
|
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.
|
Academic Article
|
A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility.
|
Academic Article
|
Breast conservation after neoadjuvant chemotherapy.
|
Academic Article
|
Improving local control with breast-conserving therapy: a 27-year single-institution experience.
|
Academic Article
|
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
|
Academic Article
|
Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy.
|
Academic Article
|
Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy.
|
Academic Article
|
Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment.
|
Academic Article
|
Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer.
|
Academic Article
|
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
|
Academic Article
|
Surgical considerations in patients receiving neoadjuvant systemic therapy.
|
Academic Article
|
The role of surgery in the multidisciplinary management of patients with localized gastrointestinal stromal tumors.
|
Academic Article
|
Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
|
Academic Article
|
Neoadjuvant chemotherapy, locally advanced breast cancer, and quality of life.
|
Academic Article
|
Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
|
Academic Article
|
Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy.
|
Academic Article
|
Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks.
|
Academic Article
|
Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT).
|
Academic Article
|
Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score.
|
Academic Article
|
Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy.
|
Academic Article
|
Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis.
|
Academic Article
|
Staging of breast cancer in the neoadjuvant setting.
|
Academic Article
|
Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation.
|
Academic Article
|
Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer.
|
Academic Article
|
Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients.
|
Academic Article
|
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer.
|
Academic Article
|
Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer.
|
Academic Article
|
Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy.
|
Academic Article
|
Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy.
|
Academic Article
|
Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy.
|
Academic Article
|
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
|
Academic Article
|
SLN surgery for clinically node-positive breast cancer patients treated with neoadjuvant therapy.
|
Academic Article
|
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
|
Academic Article
|
Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas.
|
Academic Article
|
Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
|
Academic Article
|
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
|
Academic Article
|
Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
|
Academic Article
|
Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy.
|
Academic Article
|
The neoadjuvant approach in breast cancer treatment: it is not just about chemotherapy anymore.
|
Academic Article
|
Incorporation of adjuvant therapy into the multimodality management of gastrointestinal stromal tumors of the stomach in the United States.
|
Academic Article
|
Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer.
|
Academic Article
|
The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
|
Academic Article
|
Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy.
|
Academic Article
|
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.
|
Academic Article
|
Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy.
|
Academic Article
|
Biomarkers in neoadjuvant trials.
|
Academic Article
|
Implementation of the american college of surgeons oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy?
|
Academic Article
|
Neoadjuvant therapy in the treatment of breast cancer.
|
Academic Article
|
Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial.
|
Academic Article
|
Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.
|
Academic Article
|
Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).
|
Academic Article
|
Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance).
|
Academic Article
|
Spotlight on neoadjuvant therapy for breast cancer.
|
Academic Article
|
Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy.
|
Academic Article
|
Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma.
|
Academic Article
|
Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment.
|
Academic Article
|
Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer.
|
Academic Article
|
Axillary Surgery After Chemotherapy: Challenges and Opportunities.
|
Academic Article
|
Response to preoperative endocrine therapy in breast cancer patients can alter surgical and chemotherapy options.
|
Academic Article
|
Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
|
Academic Article
|
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
|
Academic Article
|
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
|
Academic Article
|
Improved axillary evaluation following neoadjuvant therapy for patientswith node-positive breast cancer using selective evaluation of clipped nodes
|
Academic Article
|
Spotlight on Neoadjuvant Therapy for Breast Cancer
|
Academic Article
|
Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance).
|
Academic Article
|
Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).
|
Academic Article
|
Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer.
|
Academic Article
|
The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.
|
Academic Article
|
Limiting Axillary Surgery for Patients with Initial Biopsy-Proven Axillary Metastases After Preoperative Chemotherapy: To Clip or Not to Clip?
|
Academic Article
|
Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study.
|
Academic Article
|
Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer.
|
Academic Article
|
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.
|
Academic Article
|
Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer.
|
Academic Article
|
Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
|
Academic Article
|
Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance).
|
Academic Article
|
Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members.
|
Academic Article
|
Expanding Implementation of ACOSOG Z0011 in Surgeon Practice.
|
Academic Article
|
Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).
|
Academic Article
|
Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy.
|
Academic Article
|
Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis.
|
Academic Article
|
Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy.
|
Academic Article
|
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.
|
Academic Article
|
Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
|
Academic Article
|
Impact of Radiation on Locoregional Control in Women with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Lymph Node Dissection: Results from ACOSOG Z1071 Clinical Trial.
|
Academic Article
|
Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection.
|
Academic Article
|
Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer.
|
Academic Article
|
Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors.
|
Academic Article
|
Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients.
|
Academic Article
|
Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy.
|
Academic Article
|
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
|
Academic Article
|
Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031).
|
Academic Article
|
Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI.
|
Academic Article
|
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer.
|
Academic Article
|
Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer.
|
Academic Article
|
Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs.
|
Academic Article
|
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.
|